Holen Sie sich die Stockscreener-App
154.81
3.00%
-4.78
Handel nachbörslich:
154.81
Schlusskurs vom Vortag:
$159.59
Offen:
$159.59
24-Stunden-Volumen:
1.83M
Relative Volume:
0.73
Marktkapitalisierung:
$33.42B
Einnahmen:
$606.42M
Nettoeinkommen (Verlust:
$-1.28B
KGV:
-24.18
EPS:
-6.403
Netto-Cashflow:
$-997.58M
1W Leistung:
-4.69%
1M Leistung:
+7.62%
6M Leistung:
-4.63%
1J Leistung:
+138.87%
1-Tages-Spanne:
$152.99
$160.21
1-Wochen-Bereich:
$152.99
$166.19
52-Wochen-Spanne:
$63.81
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
154.81 | 34.45B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed (INSM): Top QQQ Stock to Buy Now - Yahoo Finance
Insmed Achieves $280 Million Trading Volume, Secures Leading Market Position Despite Positive Analyst Ratings and Clinical Challenges - Bitget
Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More - 24/7 Wall St.
Is It Too Late To Consider Insmed (INSM) After A 146% One Year Surge? - Yahoo Finance
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
FRANKLIN GROWTH OPPORTUNITIES FUND's Insmed Inc(INSM) Holding History - GuruFocus
Insmed (INSM) Halts Brensocatib R&D After Trial Setback - GuruFocus
Insmed chair and CEO William Lewis sells $1.75 million in stock - Investing.com
Insmed Insider Sold Shares Worth $1,746,336, According to a Recent SEC Filing - Moomoo
Insmed (INSM) CEO sells shares, exercises options under 10b5-1 plan - Stock Titan
Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake - Yahoo Finance
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure - Yahoo Finance
Insmed Drug Misses Primary Goal, Program Axed - Benzinga
Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Fails to Meet Endpoints - Minichart
AVIP AB Mid Cap Core Portfolio's Insmed Inc(INSM) Holding History - GuruFocus
Insmed (INSM) Maintains Buy Rating Despite Trial Setback - GuruFocus
Insmed (INSM) to Resume Trading After Phase 2b Study Results - GuruFocus
Insmed (INSM) Shares Dip 2% After Trading Resumes - GuruFocus
Insmed (INSM) Halts Brensocatib Development for Hidradenitis Sup - GuruFocus
Insmed stock falls after failed hidradenitis suppurativa trial By Investing.com - Investing.com Canada
Insmed announced that its latest study failed to meet both the predefined primary and secondary efficacy endpoints. - Bitget
Brensocatib HS trial misses endpoints as Insmed (INSM) shuts CEDAR program - Stock Titan
Insmed Provides Clinical Update on Phase 2b CEDAR Study - PR Newswire
Net current asset value per share of Insmed Incorporated – BX:IM8N - TradingView
RBC Capital Adjusts Price Target on Insmed to $212 From $203, Maintains Outperform Rating - Moomoo
Proposed Common stock sale by INSM (NASDAQ: INSM) with insider William Lewis activity - Stock Titan
Market Rankings: What are the risks of holding Insmed Incorporated2026 Support & Resistance & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Cacchillo v. Insmed Inc. - Law.com
Aberdeen Group plc Buys 18,490 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Stock Jumps 29% on Encouraging PAH Study Results - MSN
141,517 Shares in Insmed, Inc. $INSM Purchased by Perpetual Ltd - MarketBeat
October Effect Ltd Acquires Shares of 12,121 Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance Singapore
Roger Adsett Sells 88,060 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed (INSM) COO exercises options, sells 88,060 preplanned shares - Stock Titan
Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use - Yahoo Finance
Insmed, Inc. $INSM Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Quarterly Risk: Why is Insmed Incorporated stock going upMarket Activity Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Insmed Inc. R (IM8N.DU) Stock Price, News, Quote & History - ca.finance.yahoo.com
Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 19,638 Shares - MarketBeat
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of "Buy" from Analysts - MarketBeat
Barclays Raises Price Target for Insmed (INSM) to $237 | INSM St - GuruFocus
INSM (NASDAQ: INSM) insider lists proposed Common share sales in Form 144 - Stock Titan
[ARS] INSMED Inc SEC Filing - Stock Titan
Insmed (NASDAQ: INSM) details $606M revenue and 150% stock gain - Stock Titan
Options Bulls Could Be Right About This Pharma Stock - Finviz
INSMED (INSM) CLO exercises options and sells 19,638 shares under 10b5-1 plan - Stock Titan
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Insmed (INSM) - The Globe and Mail
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
3.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):